Myositis awaits effective treatment after negative results with bimagrumab

Patients with inclusion body myositis will have to continue to wait for an effective treatment since the latest randomised controlled trial of a potential therapy failed to impress. The phase 2b RESILIENT study of bimagrumab versus placebo found no improvement in the primary outcome of six-minute walk distance (6MWD) or secondary outcomes including isometric muscle ...

Already a member?

Login to keep reading.

© 2021 the limbic